Amitha Rao MD, Presenter: Nothing to Disclose

Eashwer K. Reddy MD, Abstract Co-Author: Nothing to Disclose

Jeffrey Holzbeierlein MD, Abstract Co-Author: Nothing to Disclose

Peter VanVeldhuizen MD, Abstract Co-Author: Nothing to Disclose

Prasanth Reddy MD, Abstract Co-Author: Nothing to Disclose

Reginald William Dusing MD, Abstract Co-Author: Nothing to Disclose

Mark Murphy BS, Abstract Co-Author: Nothing to Disclose

Jon Ternus PharmD, Abstract Co-Author: Nothing to Disclose

Darren Klish MD, Abstract Co-Author: Nothing to Disclose

Matthew Mayo PhD, Abstract Co-Author: Nothing to Disclose

Chris McMillin, Abstract Co-Author: Nothing to Disclose

et al, Abstract Co-Author: Nothing to Disclose

et al, Abstract Co-Author: Nothing to Disclose

To compare 111In-CYT-356 (ProstaScint™) with 11C-acetate PET/CT imaging in patients with biochemical evidence (a rising PSA) of recurrent prostate cancer.

For the ProstaScint™ imaging, 5 mCi of 111In-CYT was injected intravenously with planar whole body images and SPECT pelvic images acquired 20 minutes post injection, utilizing a Siemens Multi-SPECT integrated whole body/SPECT gamma camera. Similar acquisitions were obtained on days 4 and 6 post injection. For the 11C-acetate PET/CT sequence, a CT scan for attenuation correction (CTAC) and anatomical reference was obtained from the base of the brain to the proximal thigh utilizing a General Electric Discovery ST/16 slice CT scanner. The PET acquisition started 7 to 10 minutes after IV injection of 40 mCi of 11C-acetete. Patient inclusion criteria were men with histological confirmation of primary prostate cancer, status post-operative radical prostatectomy as primary treatment of prostate cancer, no other treatment modalities for prostate cancer (such as radiation therapy), PSA of greater than 0.2ng/ml, and referral for a ProstaScint™ scan. Patients were excluded from the trial if treated with any other modality other than prostatectomy, a diagnosis of other malignancy, or ECOG performance status score greater than 2.

16 volunteers underwent both ProstaScint™ and 11C-acetate PET/CT imaging. All patients diagnosed as positive on ProstaScint™ imaging had positive finding on 11C-acetate PET/CT imaging at identical sites. In addition, a significant number of patients had additional sites seen on 11C-acetate PET/CT not seen on ProstaScint™ imaging, and at lower PSA levels.

Our results suggest that while ProstaScint™ is the current diagnostic standard, 11C-acetate may be a more sensitive tool for detecting sites of prostate cancer recurrence.

Our results suggest 11C-acetate PET/CT may be the new standard for triaging recurrent prostate cancer patients into 2 treatment groups, those with local recurrence and distant metastasis.

Rao, A, Reddy, E, Holzbeierlein, J, VanVeldhuizen, P, Reddy, P, Dusing, R, Murphy, M, Ternus, J, Klish, D, Mayo, M, McMillin, C, et al, , et al, , Comparing ProstaScint™ to ¹¹ C-acetate PET/CT In Detecting Recurrent Prostate Cancer.  Radiological Society of North America 2007 Scientific Assembly and Annual Meeting, November 25 - November 30, 2007 ,Chicago IL. http://archive.rsna.org/2007/5008133.html